Agreements reached under this partnership
Business alliance- 1
Execution of an exclusive license agreement relating to the development and commercialization of a CADASIL treatment using naturally occurring human adrenomedullin
- 2
Acquisition of exclusive rights in Japan, South Korea and Taiwan to practice patents relating to adrenomedullin and use the associated clinical trial data
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact of this matter on results for the current fiscal year is expected to be minor, but the company believes it will contribute to an increase in corporate value over the medium to long term.
| Item | Details |
|---|---|
| Name of alliance partner | ひむかAMファーマ Co., Ltd., National Research and Development Agency National Cerebral and Cardiovascular Center |
| Alliance partner's business activities | A venture company originating from the University of Miyazaki that promotes drug discovery research. Through pharmaceutical development and licensing relating to adrenomedullin, it aims to create new treatment options for diseases with significant unmet medical needs., A national research and development agency established to overcome cardiovascular and cerebrovascular diseases, with an integrated research structure covering basic through clinical research. It promotes cutting-edge research and medical care relating to cardiovascular and cerebrovascular diseases. |
| Alliance partner's location | Miyazaki, Miyazaki Prefecture, Suita, Osaka |
| Type of alliance | Business alliance |
| Details of the alliance | Execution of an exclusive license agreement relating to the development and commercialization of a CADASIL treatment using naturally occurring human adrenomedullin, Acquisition of exclusive rights in Japan, South Korea and Taiwan to practice patents relating to adrenomedullin and use the associated clinical trial data |
| Impact on Business Performance | The impact of this matter on results for the current fiscal year is expected to be minor, but the company believes it will contribute to an increase in corporate value over the medium to long term. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company will develop and commercialize a CADASIL treatment using adrenomedullin, based on the National Cerebral and Cardiovascular Center's basic and clinical research findings, as a new therapeutic approach for a disease for which no established treatment exists. The initiative is positioned as a growth step toward the full-scale expansion of its pharmaceutical business.